# ACE-LY-308 (NCT02972840)

> A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

No report yet. It can be ordered.

- Drugs tested: acalabrutinib
- Indication: previously untreated mantle cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02972840
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Acerta Pharma BV
- Conditions: Lymphoma, Mantle Cell
- Interventions: Acalabrutinib; Bendamustine; Rituximab; Placebo
- Enrollment: 635
- Primary outcome: Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2

## Indexed commentary on ACE-LY-308 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ace-ly-308-nct02972840